サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1239686

糖鎖生物学：診断薬および治療薬の世界市場

Glycobiology: Global Markets for Diagnostics and Therapeutics
出版日: | 発行: BCC Research | ページ情報: 英文 123 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
糖鎖生物学：診断薬および治療薬の世界市場
出版日: 2023年03月14日
発行: BCC Research
ページ情報: 英文 123 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の糖鎖生物学の市場規模は、2022年の32億米ドルから、2027年には53億米ドルに達し、2022年から2027年にかけての予測期間中は11.1%のCAGRで成長すると予測されています。

治療薬の部門は、2022年の24億米ドルから、2027年には41億米ドルに達し、同期間中はCAGR11.2％で成長すると予測されています。また、診断薬の部門は、2022年の6億9,090万米ドルから、2027年には12億米ドルに達し、同期間中はCAGR10.7％で成長すると予測されています。

当レポートでは、世界の糖鎖生物学の市場を調査し、市場概要、市場成長への各種影響因子の分析、関連法規制、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場力学

  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第4章 市場概要

  • 概要
    • 糖生物学
    • 糖鎖の重要性
    • 糖鎖の機能とその生物学的重要性
    • 糖鎖の構造的役割
    • 糖鎖生物学研究のための研究ツール
    • 糖鎖の構造解析
    • 糖鎖生物学研究の一環としての糖鎖学
    • グリカンおよび複合糖質の化学的および酵素的合成
    • 糖生物学研究のためのバイオインフォマティクスとデータベースリソース
  • 現在の市場動向
  • 最近の戦略的提携
  • 新技術

第5章 COVID-19が市場に与える影響

  • 概要
  • COVID-19による危機

第6章 糖鎖生物学による治療薬市場

  • 概要
    • サブカテゴリー
    • 治療用糖タンパク質
    • 代謝性疾患に対する糖鎖治療アプローチ
    • グリコサミノグリカンの治療への応用
    • ワクチン成分としての炭水化物ベースのワクチンとグリカン
    • 疾患における糖鎖認識の阻害
    • 抗糖鎖抗体別輸血・移植拒絶反応

第7章 糖生物学による診断薬市場

  • 概要
    • 糖バイオマーカーと自己免疫
    • 炎症性腸疾患における糖バイオマーカー
    • 特定のニューロパシーにおける神経糖鎖に対する自己抗体
    • 心血管疾患における糖生物学マーカー
    • アルツハイマー病の組織病理学における糖鎖の役割
    • 糖バイオマーカーと喘息
    • 感染症検査における糖バイオマーカー
    • 糖生物学ベースバイオマーカーと診断検査の市場の可能性
    • 糖鎖生物学ベースの癌バイオマーカーと診断薬の開発
    • 潜在的な血清バイオマーカーとしての炭水化物
    • 現在上市済みの糖生物学ベース診断薬
    • 糖生物学診断プラットフォームと開発中の製品を有する企業
    • 糖生物学ベース診断薬の市場

第8章 糖生物学試薬およびツール市場

  • 概要
    • 分析およびクロマトグラフィー技術
    • グリカンアレイ
    • レクチンアレイ
    • 糖生物学キット
    • 糖鎖生物学研究用試薬
    • 炭水化物：単糖、オリゴ糖、その他の試薬

第9章 市場内訳：地域別

  • 概要
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第10章 市場機会の分析

  • ポーターのファイブフォース分析

第11章 競合情勢

第12章 企業プロファイル

  • 主要企業
  • AGILENT TECHNOLOGIES
  • AMSBIO LLC
  • BIO-TECHNE
  • ISOSEP
  • LUDGER LTD.
  • MERCK KGAA
  • NEW ENGLAND BIOLABS
  • TAKARA BIO INC.
  • THERMO FISHER SCIENTIFIC INC.
  • WATERS CORP.

第13章 付録：頭字語

図表

List of Tables

  • Summary Table : Global Market for Glycobiology, by Segment, Through 2027
  • Table 1 : Global Diabetes Prevalence, Estimates and Projections, 2019-2045
  • Table 2 : Cases of Diabetes Worldwide, by Type, 2019
  • Table 3 : Global Prevalence of Diabetes, by Type, Through 2040
  • Table 4 : Global HIV Epidemic, by Age Group, 2020
  • Table 5 : Market Players: R&D Investment, 2019-2021
  • Table 6 : Classification of Carbohydrates
  • Table 7 : Examples of Glycosylation Deficiency and Their Pathological Effect
  • Table 8 : Experimental Approaches to Studying Glycans
  • Table 9 : Examples of Inhibitors/Modulators Used in Glycobiology Research
  • Table 10 : Separation and Identification Techniques Used for Glycan Analysis
  • Table 11 : Bioinformatics and Database Resources for Glycobiology Research
  • Table 12 : Strategic Alliances in the Market for Glycobiology, 2020-2022
  • Table 13 : Approved Glycobiology-related Treatments and Carbohydrate-based Drugs
  • Table 14 : Global Market for Glycobiology Therapeutics, by Region, Through 2027
  • Table 15 : Glycobiology-based Markers
  • Table 16 : Global Death Share, by Various Cancer Types, 2015
  • Table 17 : FDA-approved Cancer Biomarkers Currently Used in Clinical Practice
  • Table 18 : Examples of Potential Glycoprotein Cancer Biomarkers
  • Table 19 : Companies with Diagnostic Products in Development Based on Glycobiology Research
  • Table 20 : Global Market for Glycobiology Diagnostics, by Region, Through 2027
  • Table 21 : Companies Offering Glycobiology Reagents
  • Table 22 : Global Market for Glycobiology Reagents and Tools, by Region, Through 2027
  • Table 23 : Global Market for Glycobiology, by Region, Through 2027
  • Table 24 : Diabetes Estimates in North America, by Country, 2000-2045
  • Table 25 : Influenza Disease Burden, by Age Group, U.S., 2019 and 2020 Influenza Season
  • Table 26 : North American Market for Glycobiology, by Country, Through 2027
  • Table 27 : Diabetes Estimates in Europe, by Country, 2000-2045
  • Table 28 : European Market for Glycobiology, by Country, Through 2027
  • Table 29 : Tuberculosis Burden of Asian Countries, by Country, 2019
  • Table 30 : Diabetes Estimates for the Asia-Pacific Region, by Country, 2000-2045
  • Table 31 : Asia-Pacific Market for Glycobiology, by Country, Through 2027
  • Table 32 : Diabetes Estimates in RoW, by Country, 2000-2045
  • Table 33 : New Cancer Cases in Africa, by Cancer Type, 2020 and 2024
  • Table 34 : Porter's Five Forces Analysis: Glycobiology Market
  • Table 35 : Agilent Technologies: Product Portfolio
  • Table 36 : Agilent Technologies: Key Developments, 2016-2020
  • Table 37 : AMSBIO LLC: Product Portfolio
  • Table 38 : AMSBIO LLC: Key Developments, 2022
  • Table 39 : Bio-Techne: Product Portfolio
  • Table 40 : IsoSep: Product Portfolio
  • Table 41 : Ludger Ltd.: Product Portfolio
  • Table 42 : Ludger Ltd.: Key Developments, 2022
  • Table 43 : Merck KGaA: Product Portfolio
  • Table 44 : Merck KgaA: Key Developments, 2020 and 2021
  • Table 45 : New England Biolabs: Insulin Product Portfolio
  • Table 46 : Takara Bio Inc.: Product Portfolio
  • Table 47 : Thermo Fisher Scientific Inc.: Product Portfolio
  • Table 48 : Thermo Fisher Scientific Inc.: Key Developments, 2020
  • Table 49 : Waters Corp.: Product Portfolio
  • Table 50 : Acronyms Used in This Report

List of Figures

  • Summary Figure : Global Market Shares of Glycobiology, by Segment, 2021
  • Figure 1 : Emerging Glycomics Technologies
  • Figure 2 : Cases of Diabetes Worldwide, by Type, 2019
  • Figure 3 : Global Prevalence of Diabetes, by Type, 2018-2040
  • Figure 4 : Numbers and Shares of New Cancer Cases, Women, 2020
  • Figure 5 : Numbers and Shares of New Cancer Cases, Men, 2020
  • Figure 6 : Schematic Presentation of O- and N-linked Glycans on Protein Receptor
  • Figure 7 : Global Market for Glycobiology Therapeutics, 2019-2027
  • Figure 8 : Global Market for Glycobiology Diagnostics, 2019-2027
  • Figure 9 : Global Market for Glycobiology Reagents and Tools, 2019-2027
  • Figure 10 : Global Market Shares of Glycobiology, by Region, 2021
  • Figure 11 : North American Market Shares of Glycobiology, by Country, 2021
  • Figure 12 : Cancer Diagnosis Share in Europe, by Gender, 2020
  • Figure 13 : European Market Shares of Glycobiology, by Country, 2021
  • Figure 14 : Asia-Pacific Market Shares of Glycobiology, by Country, 2021
  • Figure 15 : Global Market Shares of Glycobiology, by Company, 2021
  • Figure 16 : Agilent Technologies: Annual Revenue, 2019-2021
  • Figure 17 : Agilent Technologies: Revenue Share, by Segment, 2021
  • Figure 18 : Agilent Technologies: Revenue Share, by Region, 2021
  • Figure 19 : Bio-Techne: Annual Revenue, 2019-2021
  • Figure 20 : Bio-Techne: Revenue Share, by Business Segment, 2021
  • Figure 21 : Bio-Techne: Revenue Share, by Region, 2021
  • Figure 22 : Merck KGaA: Annual Revenue, 2019-2021
  • Figure 23 : Merck KGaA: Revenue Share, by Business Segment, 2021
  • Figure 24 : Merck KGaA: Revenue Share, by Region, 2021
  • Figure 25 : Takara Bio Inc.: Annual Revenue, 2019-2021
  • Figure 26 : Takara Bio Inc.: Revenue Share, by Segment, 2021
  • Figure 27 : Takara Bio Inc.: Revenue Share, by Region, 2021
  • Figure 28 : Thermo Fisher Scientific Inc.: Annual Revenue, 2019-2021
  • Figure 29 : Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2021
  • Figure 30 : Thermo Fisher Scientific Inc.: Revenue Share, by Region, 2021
  • Figure 31 : Waters Corp.: Annual Revenue, 2019-2021
  • Figure 32 : Waters Corp.: Revenue Share, by Segment, 2021
  • Figure 33 : Waters Corp.: Revenue Share, by Region, 2021
目次
Product Code: BIO153B

Highlights:

The global glycobiology market should reach $5.3 billion by 2027 from $3.2 billion in 2022 at a compound annual growth rate (CAGR) of 11.1% for the forecast period of 2022 to 2027.

Glycobiology therapeutics segment of the global glycobiology market is expected to grow from $2.4 billion in 2022 to $4.1 billion in 2027 at a CAGR of 11.2% for the forecast period of 2022 to 2027.

Glycobiology diagnostics segment of the global glycobiology market is expected to grow from $690.9 million in 2022 to $1.2 billion in 2027 at a CAGR of 10.7% for the forecast period of 2022 to 2027.

Report Scope:

The current report will provide an in-depth look at the glycobiology market. This report analyzes glycobiology market trends with data from 2021, estimates for 2022, projections of compound annual growth rates through 2027 (forecast period of 2022 to 2027), and regional market data. This report will highlight the current and future market potential of glycobiology along with providing a detailed analysis of the competitive environment. Regulatory scenarios, drivers, restraints, and opportunities will be covered in the current report. The report also covers market projections for 2027 and indicates the market share for key market players.

The scope of the market in this report is segmented into glycobiology segment and region. The segments of glycobiology are: glycobiology therapeutics, glycobiology diagnostics, and glycobiology reagents and tools. The regional markets are North America, Europe, Asia-Pacific, and other world regions (Rest of the World). Detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Japan, China, and India will be covered within their respective regional segments. For market estimates, data will be provided for 2021 as the base year, with forecasts for 2022 and 2027.

Report Includes:

  • 51 tables
  • An up-to-date overview and analysis of the global markets for glycobiology diagnostics and therapeutics
  • Analyses of the global market trends, with historic revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the market potential for glycobiology market, industry growth drivers, and areas of focus to forecast this market into various segments and subsegments
  • Estimation of the actual market size and revenue forecast for global glycobiology market in USD million terms, and corresponding market share analysis by major market segments and region
  • A look at new tools for synthesizing, modifying and studying oligosaccharides and glycoconjugates
  • Evaluation of promising candidates for carbohydrate-based diagnostics, drugs and vaccines
  • Insight into how glycobiology offers enormous untapped potential in the discovery of new therapeutics derived from saccharides or other molecules which target the biosynthesis and function of saccharides
  • Identification of leading biotechnology companies poised to introduce products during the forecast period, and their impact on the face of the competitive environment
  • Insight into recent industry structure for glycobiology diagnostics and therapeutics, current competitive scenario, clinical trials, ongoing research (R&D) activities, strategic alliances, and COVID-19 impact on the progress of this market
  • Profile descriptions of the major market players, including Agilent Technologies Inc., Bio-Techne, Merck KGaA, Takara Bio Inc. and Waters Corp.

Table of Contents

Chapter 1 Introduction

  • 1.1 Overview
  • 1.2 Study Goals and Objectives
  • 1.3 Reasons for Doing This Study
  • 1.4 What's New in This Update?
  • 1.5 Scope of Report
  • 1.6 Information Sources
  • 1.7 Methodology
  • 1.8 Geographic Breakdown
  • 1.9 Analyst's Credentials
  • 1.10 BCC Custom Research
  • 1.11 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Dynamics

  • 3.1 Market Drivers
    • 3.1.1 Technological Advancements in the Analysis of Glycans
    • 3.1.2 Rising Prevalence of Chronic Disorders Globally
    • 3.1.3 Increasing R&D Investment by Pharma Companies
  • 3.2 Market Restraints
    • 3.2.1 Challenges in Glycobiology
  • 3.3 Market Opportunities
    • 3.3.1 Inorganic Strategies among Market Players

Chapter 4 Market Overview

  • 4.1 Overview
    • 4.1.1 Glycobiology
    • 4.1.2 Significance of Glycan
    • 4.1.3 Function of Glycans and Their Biological Significance
    • 4.1.4 Structural Role of Glycans
    • 4.1.5 Research Tools for Glycobiology Studies
    • 4.1.6 Structural Analysis of Glycans
    • 4.1.7 Glycomics as Part of Glycobiology Research
    • 4.1.8 Chemical and Enzymatic Synthesis of Glycans and Glycoconjugates
    • 4.1.9 Bioinformatics and Database Resources for Glycobiology Research
  • 4.2 Current Market Trends
    • 4.2.1 Protein and Glycan Glycoengineering
    • 4.2.2 Engineering Glycans and Glycan Mimics as Therapeutic Agents
    • 4.2.3 Glycobiology and Drug Delivery
    • 4.2.4 Oligosaccharide Libraries for Drug Discovery Research
    • 4.2.5 Glyconutrients as Therapeutics
  • 4.3 Recent Strategic Alliances
  • 4.4 Emerging Technologies
    • 4.4.1 Glycans in Medicine and Biotechnology
    • 4.4.2 Glycans in Nanotechnology, Bioenergy, and Materials Science

Chapter 5 Impact of COVID-19 on Market

  • 5.1 Overview
  • 5.2 COVID-19 Crisis
    • 5.2.1 Impact on Market for Glycobiology
    • 5.2.2 COVID-19 Measures

Chapter 6 Glycobiology Therapeutics Market

  • 6.1 Overview
    • 6.1.1 Subcategories of Glycobiology Therapeutics
    • 6.1.2 Therapeutic Glycoproteins
    • 6.1.3 Glycan Therapeutic Approaches to Metabolic Diseases
    • 6.1.4 Therapeutic Applications of Glycosaminoglycans
    • 6.1.5 Carbohydrate-based Vaccines and Glycans as Vaccine Components
    • 6.1.6 Blocking Glycan Recognition in Diseases
    • 6.1.7 Transfusion and Transplantation Rejection by Anti-glycan Antibodies

Chapter 7 Glycobiology Diagnostics Market

  • 7.1 Overview
    • 7.1.1 Glycobiomarkers and Autoimmunity
    • 7.1.2 Glycobiomarkers in Inflammatory Bowel Disease
    • 7.1.3 Autoantibodies Against Neuronal Glycans in Certain Neuropathies
    • 7.1.4 Glycobiology Markers in Cardiovascular Diseases
    • 7.1.5 Role of Glycans in the Histopathology of Alzheimer's Disease
    • 7.1.6 Glycobiomarkers and Asthma
    • 7.1.7 Glycobiomarkers in Infectious Disease Testing
    • 7.1.8 Market Potential for Glycobiology-based Biomarkers and Diagnostic Tests
    • 7.1.9 Glycobiology-based Cancer Biomarkers and Diagnostic Development
    • 7.1.10 Carbohydrates as Potential Serum Biomarkers
    • 7.1.11 Current Glycobiology-based Diagnostics on the Market
    • 7.1.12 Companies with Glycobiology Diagnostic Platforms and Products in Development
    • 7.1.13 Market for Glycobiology-based Diagnostics

Chapter 8 Glycobiology Reagents and Tools Market

  • 8.1 Overview
    • 8.1.1 Analytical and Chromatography Techniques
    • 8.1.2 Glycan Arrays
    • 8.1.3 Lectin Arrays
    • 8.1.4 Glycobiology Kits
    • 8.1.5 Reagents for Glycobiology Research
    • 8.1.6 Carbohydrates: Monosaccharides, Oligosaccharides and Other Reagents

Chapter 9 Market Breakdown by Region

  • 9.1 Overview
    • 9.1.1 North America
    • 9.1.2 Europe
    • 9.1.3 Asia-Pacific
    • 9.1.4 Rest of the World

Chapter 10 Analysis of Market Opportunities

  • 10.1 Porter's Five Forces Analysis
    • 10.1.1 Threat of New Entrants
    • 10.1.2 Threat of Substitutes
    • 10.1.3 Bargaining Power of Suppliers
    • 10.1.4 Bargaining Power of Buyers
    • 10.1.5 Degree of Competition

Chapter 11 Competitive Landscape

Chapter 12 Company Profiles

  • 12.1 Major Companies
  • AGILENT TECHNOLOGIES
  • AMSBIO LLC
  • BIO-TECHNE
  • ISOSEP
  • LUDGER LTD.
  • MERCK KGAA
  • NEW ENGLAND BIOLABS
  • TAKARA BIO INC.
  • THERMO FISHER SCIENTIFIC INC.
  • WATERS CORP.

Chapter 13 Appendix: Acronyms